# Anhui Tongling Bionic Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anhui-tongling-bionic-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Hefei, China
- Website: www.telelife.com.cn
- Latest round: Series B (Jul 19, 2022)
- Investors on record: 2

## About

Founded in 2016 and based in Hefei, China, Anhui Tongling Bionic Technology Co., Ltd., dba TeleLife, is a medical device company focused on the development, production and sales of cardiopulmonary assisted medical devices. The company's chairman and general manager, Dr. Qilian Xie, is a postdoctoral fellow at the National Heart and Lung Institute of Imperial College, with more than 20 years of cardiovascular and critical care clinical experience, more than 80 domestic and international academic papers, and more than 60 domestic and international invention patents. The company has more than 100 independent innovation patents as of 2022. The company's main business is the research and development, production and sales of cardiopulmonary assisted medical devices. The company's self-developed innovative products include intra-aortic balloon pump (IABP), extracorporeal counterpulsation therapy system, non-invasive cardiac output monitor and extracorporeal membrane oxygenation equipment (ECMO). The company generates revenue from the sales of medical devices.
In January 2026, Anhui Tongling Bionic Technology Co., Ltd. closed a venture funding from new investor Changchun Equity Investment Fund Management.

## Funding rounds

- Series B, Jul 19, 2022 — Pine Capital
- Series A, Apr 9, 2019 — CAS Venture Capital

## Investors

- CAS Venture Capital (https://capitalatlas.ai/funds/cas-venture-capital) — Series A
- Pine Capital (https://capitalatlas.ai/funds/pine-capital) — Series B